Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases

Time: 4:30 pm
day: Day Two


  • Examine how degraders are heterobifunctional molecules that redirect E3 ligase activity to selectively remove dysregulated proteins of interest via the UPS, that offer an exciting new therapeutic approach for immune targets
  • Unveil how targeting IRAK4 for degradation leads to potent anti-inflammatory responses of TLR activated B cells compared to small-molecule inhibition
  • STAT3 degradation abrogates Th17 development with commensurate T reg increases